Clinical Research Directory
Browse clinical research sites, groups, and studies.
The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants.
Sponsor: Princess Anna Mazowiecka Hospital, Warsaw, Poland
Summary
The aim of this study will be to assess the effectiveness of monitored vit D supplementation in a population of preterm infants and to identify whether the proper vit D supplementation in preterm infants can reduce the incidence of neonatal sepsis and incidence of metabolic bone disease.
Official title: The High Initial Dose of Monitored Vitamin D Supplementation in Preterm Infants. A Randomized Controlled Study.
Key Details
Gender
All
Age Range
1 Day - 2 Days
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2024-09-01
Completion Date
2027-12-31
Last Updated
2024-01-10
Healthy Volunteers
No
Conditions
Interventions
cholecalciferol/ Devikap
Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.
cholecalciferol/ Devikap
Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
Locations (1)
Princess Anna Mazowiecka Hospital
Warsaw, Poland